Literature DB >> 23483225

Intravaginal live attenuated Salmonella increase local antitumor vaccine-specific CD8+ T cells.

Loane Decrausaz1, Christelle Pythoud, Sonia Domingos-Pereira, Laurent Derré, Patrice Jichlinski, Denise Nardelli-Haefliger.   

Abstract

We have recently reported that the intravaginal instillation of synthetic Toll-like receptor 3 (TLR3) or TLR9 agonists after a subcutaneous vaccination against human papillomavirus E7 highly increases (~5-fold) the number of vaccine-specific CD8+ T cells in the genital mucosa of mice, without affecting E7-specific systemic responses. Here, we show that the instillation of live attenuated Salmonella enterica serovar Typhimurium similarly, though more efficiently (~15- fold), increases both E7-specific and total CD8+ T cells in the genital mucosa. Cancer immunotherapeutic strategies combining vaccination with local immunostimulation with live bacteria deserve further investigations.

Entities:  

Keywords:  CD8+ T cells; bacterial immunostimulant; genital mucosa; human papillomavirus; vaccination

Year:  2013        PMID: 23483225      PMCID: PMC3583940          DOI: 10.4161/onci.22944

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


Introduction

Therapeutic human papillomavirus (HPV) vaccines targeting the E6 and/or E7 HPV oncogenes were mainly designed to induce specific cytotoxic T lymphocyte (CTL) responses against cervical cancer, the second leading cause of cancer deaths in women worldwide. Despite impressive results in animal models, their application in humans has shown modest clinical effectiveness (reviewed in ref. 2). We have recently reported that the combination of antigen-specific vaccination followed by the induction of local inflammation by intravaginal (IVAG) instillation of Toll-like receptor (TLR) agonists (i.e., CpG oligonucleotides, CpG, a TLR9 agonist or poly(I:C), PIC, a TLR3 agonist) is able to promote the accumulation of both total and antigen-specific CTLs in the genital mucosa (GM) of mice. Most interestingly, repeated IVAG CpG instillations after E7-targeting vaccination eventually led to the regression of large genital HPV-induced tumors. GM-localized CD8+ T cells recruited in response to CpG preferentially expressed CCR5 and CXCR3 chemokine receptors and E-selectin ligands, suggesting that they accumulated in the GM through the interaction with CpG-induced CCL5, CCL3, CCL4, CXCL9, CXCL10, CXCL11 and/or E-selectin. Other TLR ligands are known to modify the expression of selectins, integrins, chemokines and chemokine receptors, which may affect T-cell migration to effector sites. Among these, live bacteria, such as Salmonella, can induce pro-inflammatory responses via bacterial components, including lipopolysaccharide (LPS, a TLR4 agonist), flagellin (a TLR5 agonist) and/or bacterial DNA (TLR9 agonist), not only when delivered orally (their normal route of infection), but also when administered in vagina. In addition, attenuated Salmonella can be easily engineered to deliver heterologous antigens, and is used as a vaccine (strain Ty21a, Vivotif®) against typhoid fever by the oral route since decades, with an excellent safety record. Here, we have investigated whether attenuated Salmonella enterica serovar Typhimurium vaccine strains would act as an IVAG immunostimulant after E7 vaccination in mice.

Result and Discussion

Intravaginal instillation of live attenuated Salmonella enterica serovar Typhimurium after a subcutaneous (s.c.) E7 vaccination increased E7-specific effector CD8+ T cells in the cervix-vagina (CV)

All C57Bl/6 mice were first synchronized in a diestrus-like status to avoid possible variations in the IVAG immunostimulatory activity along the estrous cycle. Groups of mice were s.c. immunized with a long synthetic E7 peptide together with adjuvants and 5 d later PBS (as control), CpG or ~5 x 108 CFU of PhoPc attenuated Salmonella expressing an irrelevant antigen (PhoPckanL1S) were administered in vagina. Mice were sacrificed at day 9, and cells recovered from CV were analyzed (Fig. 1) by ex-vivo interferon γ (IFNγ) ELISPOT assays using the H-2Db restricted E749–57 CTL peptide. As previously shown, IVAG CpG significantly increased (by ~5-fold) E7-specific effector CD8+ T cells in the CV (means ± SEM, E7-specific IFNγ-secreting cells/105 CV cells of 71 ± 8 as compared with 14 ± 5 after intravaginal PBS, p < 0.0001 by one-way ANOVA and Tukey’s post-test). More interestingly, intravaginal PhoPc was even more efficient, leading to a ~15-fold increased number of E7-specific IFNγ-secreting cells/105 CV cells (196 ± 46, p < 0.0001 and p < 0.05, as compared with intravaginal PBS and intravaginal CpG, respectively). The PhoPc strain has a mutation in the two-component regulatory system phoP/phoQ, which controls more than 40 different genes required for intracellular survival and resistance to innate immune defense mechanisms., We thus further tested a differently attenuated auxotrophic mutant Salmonella strain, AroA (AroAkanL1S), which depends on p-aminobenzoic acid and 2,3-dihydroxybenzoate for the synthesis of aromatic amino acids and growth. IVAG AroA after E7-vaccination also significantly increased E7-specific IFNγ-secreting cells/105 CV cells (95 ± 12, p < 0.0001 as compared with intravaginal PBS, p = non significant as compared with PhoPc). Because these bacteria can persist in the CV after intravaginal infection, we tested whether viability was influencing their intravaginal immunostimulatory ability. Indeed intravaginal heat-killed (HK) AroA bacteria were still able to significantly increase E7-specific IFNγ-secreting cells/105 CV cells (45 ± 7, p < 0.01 as compared with intravaginal PBS), though less efficiently than live AroA cells (p < 0.05 by Student's t-tests).

Figure 1. IVAG PhoPc or AroA bacteria administered after E7 immunization increased E7-specific effector CD8+ T cells in the cervix-vagina. Groups of mice were s.c. immunized with 50 μg E71–98 + 10 μg CpG + 0.4 μg Escherichia coli heat labile toxin (E7 vaccine) and 5 days later instilled in vagina with PBS, 100 μg CpG, ~5x 108 CFU of PhoPc, AroA or heat-killed (HK) AroA bacteria. Mice were sacrificed three days later and cells recovered from the cervix-vagina were analyzed by ex vivo IFNγ ELISPOT as previously described. The numbers of E749–57 specific IFNγ-secreting cells/105 cells are indicated. Horizontal bars represent mean responses. Significant differences are indicated by *p < 0.05, **p < 0.01 and ***p < 0.001 following one-way ANOVA and Tukey’s post test (GraphPad Prism 5).

Figure 1. IVAG PhoPc or AroA bacteria administered after E7 immunization increased E7-specific effector CD8+ T cells in the cervix-vagina. Groups of mice were s.c. immunized with 50 μg E71–98 + 10 μg CpG + 0.4 μg Escherichia coli heat labile toxin (E7 vaccine) and 5 days later instilled in vagina with PBS, 100 μg CpG, ~5x 108 CFU of PhoPc, AroA or heat-killed (HK) AroA bacteria. Mice were sacrificed three days later and cells recovered from the cervix-vagina were analyzed by ex vivo IFNγ ELISPOT as previously described. The numbers of E749–57 specific IFNγ-secreting cells/105 cells are indicated. Horizontal bars represent mean responses. Significant differences are indicated by *p < 0.05, **p < 0.01 and ***p < 0.001 following one-way ANOVA and Tukey’s post test (GraphPad Prism 5).

Bacterial expression of E7 modestly improved the recruitment of E7-specific CD8+ T cells in the cervix-vagina upon IVAG instillation

We wondered whether the expression of E7 by IVAG bacteria may further increase the recruitment of E7-specific CD8+ T cells in the CV by locally boosting vaccine-specific immune responses. For this purpose, we engineered a PhoPc strain that carried a plasmid (pFSnsd-kan3-mtHsp70HPV16E7Δ21–26E6Δ118−122, Fig. 2A) expressing, under the prokaryotic trc promoter, non-oncogenic forms of E7 (E7Δ21–26) and E6 (E6Δ118−122) fused to the heat-shock protein (Hsp)70 of Mycobacterium tuberculosis (mt) (see lanes HspE7E6 in Fig. 2B)., However, the IVAG administration of the E7-expressing PhoPc (PhopcE7) bacteria following E7 vaccination was only slightly more efficient than PhoPc bacteria at increasing the number of E7-specific IFNγ-secreting cells in the CV (191 ± 42 and 167 ± 29 at day 9, respectively, p = non significant, Fig. 2C). Even when examined at a later time point (day 15) to accommodate possible local antigen-presentation and specific T-cell proliferation variations, no significant difference between the two IVAG recombinant Salmonella strains could be observed (39 ± 11and 32 ± 5, respectively, Fig. 2C). A subset of CV cells from day 9 (n = 4) were also examined by flow cytometry upon anti-CD8 and tetramer staining (TetE7, based on the H-2Db restricted E749–57 CTL peptide, see Table 1). A slightly higher number of TetE7+CD8+ cells was again observed upon IVAG PhoPcE7, as compared with IVAG PhoPc (p = non significant), administration but, more interestingly, the percentage of TetE7 CD8+ T cells among total CD8+ T cells appeared significantly higher than after the instillation of IVAG PhoPc bacteria (p < 0.001) or IVAG PBS (p < 0.05). The fact that E7-specific CD8+ T cells were enriched in the CD8+ T-cell population of the GM when IVAG Salmonella expressed E7 suggests that indeed some local boosting had occurred. This is in agreement with previous reports on the ability of recombinant PhoPc cells to induce antigen-specific antibodies and cell-mediated immune responses after IVAG immunization,, although the modest effect observed in our case suggest that the expression of E7 was too low or not enough immunogenic in our recombinant PhoPc strain after a single IVAG instillation. Indeed, PhoPcE7 bacteria were also unable to prevent tumor implantation when used as a vaccine in a prophylactic setting (data not shown). Given the accumulating success of Salmonella as gene delivery system, new constructs using an eukaryotic promoter for E7 expression would be worth testing. Interestingly, and despite of the fact that PhoPc bacteria are surviving for three weeks in the CV at 104 CFU, the E7-specific response was greatly decreased at day 15, as compared with day 9 (p < 0.01), though it was still significantly higher than after the IVAG administration of PBS (p < 0.05). This may suggest that an IVAG dose of 104 CFU is not sufficient to maintain a high number of E7-specific CD8+ T cells in the CV or, on the contrary, that the chronic presence of bacteria is counterproductive. In the case of CpG, three consecutive IVAG doses administered at days 6, 9 and 12 were able to sustain a high E7-specific immune response until day 15, while successive PIC instillation were ineffective. The analysis of peripheral blood mononuclear cells (PBMCs), spleen and lymph node draining the genital tract (GLN) (Table 2) confirms that the effect of IVAG bacteria on E7-specific CD8+ T-cell recruitment was restricted to the GM, as similar or rather lower number of E7-specific IFNγ-secreting cells were measured among PBMCs as well as in the GLN and spleen. Our flow cytometry analysis also indicates that the percentage of TetE7+ CD8+ cells in the CV of E7-vaccinated mice that had received IVAG PhoPc or PhoPcE7 cells were increased ~15-fold as compared with IVAG PBS instillation and a similar fold-increase was measured for total CD8+ T cells (Table 1). This confirms that IVAG Salmonella after E7 vaccination mainly promote the recruitment of CD8+ T cells, including E7 vaccine-specific cells, from the periphery. The chemokines and/or selectines involved in this process will have to be investigated. However, it is noteworthy that, similarly to CpG, Salmonella enterica serovar Typhimurium can induce the upregulation of CCL3, CCL4, CXCL9, CXCL10, CXCL11 and E-selectin in the intestinal mucosa., The fact that both CCL5 and CXCL10 are secreted by macrophages and dendritic cells upon Salmonella infection, while purified LPS or flagellin were less efficient in this respect, may support our finding that live bacteria are superior immunostimulants than purified bacterial components. The ligands of CXCR3 and CCR5 reportedly increase in the GM 24h after IVAG infection with PhoPc and/or AroA bacteria, returning to steady-state levels 6 days later, which may possibly correlate to the decreased T-cell recruitment we observed at day 15.

Figure 2. Bacterial expression of E7 modestly influenced the fold-increase of E7-specific CD8+ T cells in the cervix-vagina upon intravaginal instillation. (A) The plasmid pFSnsd-kan3-mtHsp70HPV16E7Δ21–26E6Δ118−122 contains within the NcoI and HindIII restrictions sites, instead of L1S, a sequence encompassing the full lenght Mycobacterium tuberculosis (mt) heat-shock protein 70 (Hsp70) open reading frame (ORF) fused to the E7 ORF deleted from residues 21 to 26 and the E6 ORF deleted from residues 118–122. (B). Expression of the fusion protein (~100 KDa) in PhoPc bacterial lysates (lane HspE7E6) is detected with polyclonal anti-E7 and anti-E6 antibodies (kindly provided by Dr. John Schiller, NCI, Bethesda, USA) as well as with a monoclonal anti-mtHsp70 antibody (HyTest Ltd, Turku, Finland). For comparison, E7 and E6 only are detected in bacterial lysates from PhoPc cells expressing an E7-E6 fusion without Hsp70 (~32 KDa). (C) Mice s.c. immunized with the adjuvanted E7 vaccine and receiving 5 d later intravaginal PBS, CpG, PhoPc or PhoPcE7 cells were sacrificed at day 9 (left) or at day 15 (right) and cells recovered from cervix-vagina were analyzed by ex vivo IFNγ ELISPOT. The numbers of E749–57- specific IFNγ-secreting cells/105 cells are indicated. Horizontal bars represent mean responses. Significant differences are indicated by *p < 0.05 and *** p < 0.001 following one-way ANOVA and Tukey’s post test (GraphPad Prism 5).

Table 1. TetE7 CD8+ and total CD8+ T cells in the genital mucosa (n=4) after IVAG instillation of Phopc bacteria expressing or not E7

IVAG immunostimulantTetE7+CD8+Total CD8+ T cells% TetE7+CD8+/total CD8+
PBS
0.12±0.04
0.66±0.19
17.4±0.4
Phopc
1.83±0.43***
10.94±3.06***
16.9±0.9
PhopcE72.28±0.31*** 9.57±0.92***22.6±0.8*, ¶¶

Mean percentages±SEM; *p< 0.05 as compared to IVAG PBS; *** p< 0.001as compared to IVAG PBS; ¶¶ p< 0.001 as compared to IVAG PhoPc

Table 2. Systemic E7-specific IFNγ-secreting cells /105 cells at day 9

IVAG immunostimulantPBMCSpleenGLN
PBS
296±87
164±32
24±10
CpG
417± 82
103±20
41±8
PhoPc
159±53
59±14*
26±8
PhoPcE7108± 15 86±1922±6

Means±SEM; *p< 0.05 as compared to intravaginal PBS

Figure 2. Bacterial expression of E7 modestly influenced the fold-increase of E7-specific CD8+ T cells in the cervix-vagina upon intravaginal instillation. (A) The plasmid pFSnsd-kan3-mtHsp70HPV16E7Δ21–26E6Δ118−122 contains within the NcoI and HindIII restrictions sites, instead of L1S, a sequence encompassing the full lenght Mycobacterium tuberculosis (mt) heat-shock protein 70 (Hsp70) open reading frame (ORF) fused to the E7 ORF deleted from residues 21 to 26 and the E6 ORF deleted from residues 118–122. (B). Expression of the fusion protein (~100 KDa) in PhoPc bacterial lysates (lane HspE7E6) is detected with polyclonal anti-E7 and anti-E6 antibodies (kindly provided by Dr. John Schiller, NCI, Bethesda, USA) as well as with a monoclonal anti-mtHsp70 antibody (HyTest Ltd, Turku, Finland). For comparison, E7 and E6 only are detected in bacterial lysates from PhoPc cells expressing an E7-E6 fusion without Hsp70 (~32 KDa). (C) Mice s.c. immunized with the adjuvanted E7 vaccine and receiving 5 d later intravaginal PBS, CpG, PhoPc or PhoPcE7 cells were sacrificed at day 9 (left) or at day 15 (right) and cells recovered from cervix-vagina were analyzed by ex vivo IFNγ ELISPOT. The numbers of E749–57- specific IFNγ-secreting cells/105 cells are indicated. Horizontal bars represent mean responses. Significant differences are indicated by *p < 0.05 and *** p < 0.001 following one-way ANOVA and Tukey’s post test (GraphPad Prism 5). Mean percentages±SEM; *p< 0.05 as compared to IVAG PBS; *** p< 0.001as compared to IVAG PBS; ¶¶ p< 0.001 as compared to IVAG PhoPc Means±SEM; *p< 0.05 as compared to intravaginal PBS In conclusion, our data show that the IVAG instillation of Salmonella vaccine strains after vaccination can lead to a major increase in vaccine-specific CD8+ T cell selectively in the GM, adding to the list of TLR agonists that may be used for cancer therapy. Further experiments are needed to unravel the underlying mechanisms and determine the effects of this strategy on genital HPV-associated tumor regression. Interestingly, our preliminary data (not shown) suggest that bacterial immunostimulation may be useful for tumors located in other mucosal sites. As Salmonella appears to exert a multipronged antineoplastic effect, the detailed characterization of these bacteria as local immunostimulants and antigen-delivery systems is warranted.
  26 in total

1.  Postmarketing safety surveillance for typhoid fever vaccines from the Vaccine Adverse Event Reporting System, July 1990 through June 2002.

Authors:  Elizabeth M Begier; Dale R Burwen; Penina Haber; Robert Ball
Journal:  Clin Infect Dis       Date:  2004-02-26       Impact factor: 9.079

Review 2.  Listeria and Salmonella bacterial vectors of tumor-associated antigens for cancer immunotherapy.

Authors:  Yvonne Paterson; Patrick D Guirnalda; Laurence M Wood
Journal:  Semin Immunol       Date:  2010-03-17       Impact factor: 11.130

Review 3.  The many roles of chemokines and chemokine receptors in inflammation.

Authors:  Israel F Charo; Richard M Ransohoff
Journal:  N Engl J Med       Date:  2006-02-09       Impact factor: 91.245

4.  Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine.

Authors:  R Germanier; E Füer
Journal:  J Infect Dis       Date:  1975-05       Impact factor: 5.226

5.  Prophylactic, therapeutic and anti-metastatic effects of an HPV-16mE6Delta/mE7/TBhsp70Delta fusion protein vaccine in an animal model.

Authors:  Xinlai Qian; Yuanzhi Lu; Qiao Liu; Ke Chen; Qingzheng Zhao; Jietao Song
Journal:  Immunol Lett       Date:  2005-10-05       Impact factor: 3.685

6.  A two-component regulatory system (phoP phoQ) controls Salmonella typhimurium virulence.

Authors:  S I Miller; A M Kukral; J J Mekalanos
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

7.  A recombinant Salmonella typhimurium vaccine induces local immunity by four different routes of immunization.

Authors:  S Hopkins; J P Kraehenbuhl; F Schödel; A Potts; D Peterson; P de Grandi; D Nardelli-Haefliger
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

8.  Intravaginal immunization of mice with recombinant Salmonella enterica serovar Typhimurium expressing human papillomavirus type 16 antigens as a potential route of vaccination against cervical cancer.

Authors:  Hakim Echchannaoui; Matteo Bianchi; David Baud; Martine Bobst; Jean-Christophe Stehle; Denise Nardelli-Haefliger
Journal:  Infect Immun       Date:  2008-03-10       Impact factor: 3.441

9.  Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever.

Authors:  Dominique Fraillery; David Baud; Susana Yuk-Ying Pang; John Schiller; Martine Bobst; Nathalie Zosso; Françoise Ponci; Denise Nardelli-Haefliger
Journal:  Clin Vaccine Immunol       Date:  2007-08-08

10.  Intravaginal TLR agonists increase local vaccine-specific CD8 T cells and human papillomavirus-associated genital-tumor regression in mice.

Authors:  S Domingos-Pereira; L Decrausaz; L Derré; M Bobst; P Romero; J T Schiller; P Jichlinski; D Nardelli-Haefliger
Journal:  Mucosal Immunol       Date:  2012-09-12       Impact factor: 7.313

View more
  7 in total

1.  Tissue-resident memory T cells play a key role in the efficacy of cancer vaccines.

Authors:  C Granier; C Blanc; S Karaki; T Tran; H Roussel; E Tartour
Journal:  Oncoimmunology       Date:  2017-08-08       Impact factor: 8.110

2.  Local Salmonella immunostimulation recruits vaccine-specific CD8 T cells and increases regression of bladder tumor.

Authors:  Sonia Domingos-Pereira; Rim Hojeij; Erica Reggi; Laurent Derré; Mathieu F Chevalier; Pedro Romero; Patrice Jichlinski; Denise Nardelli-Haefliger
Journal:  Oncoimmunology       Date:  2015-05-22       Impact factor: 8.110

3.  Immunotherapeutic strategies for bladder cancer.

Authors:  Mathieu F Chevalier; Denise Nardelli-Haefliger; Sonia Domingos-Pereira; Patrice Jichlinski; Laurent Derré
Journal:  Hum Vaccin Immunother       Date:  2014-01-02       Impact factor: 3.452

4.  Induction of resident memory T cells enhances the efficacy of cancer vaccine.

Authors:  Mevyn Nizard; Hélène Roussel; Mariana O Diniz; Soumaya Karaki; Thi Tran; Thibault Voron; Estelle Dransart; Federico Sandoval; Marc Riquet; Bastien Rance; Elie Marcheteau; Elizabeth Fabre; Marion Mandavit; Magali Terme; Charlotte Blanc; Jean-Baptiste Escudie; Laure Gibault; Françoise Le Pimpec Barthes; Clemence Granier; Luis C S Ferreira; Cecile Badoual; Ludger Johannes; Eric Tartour
Journal:  Nat Commun       Date:  2017-05-24       Impact factor: 14.919

Review 5.  Niches for the Long-Term Maintenance of Tissue-Resident Memory T Cells.

Authors:  Shiki Takamura
Journal:  Front Immunol       Date:  2018-05-31       Impact factor: 7.561

6.  Memory Inflation Drives Tissue-Resident Memory CD8+ T Cell Maintenance in the Lung After Intranasal Vaccination With Murine Cytomegalovirus.

Authors:  Kaitlyn M Morabito; Tracy J Ruckwardt; Erez Bar-Haim; Deepika Nair; Syed M Moin; Alec J Redwood; David A Price; Barney S Graham
Journal:  Front Immunol       Date:  2018-08-14       Impact factor: 7.561

7.  Carboplatin/paclitaxel, E7-vaccination and intravaginal CpG as tri-therapy towards efficient regression of genital HPV16 tumors.

Authors:  Sonia Domingos-Pereira; Gabriele Galliverti; Douglas Hanahan; Denise Nardelli-Haefliger
Journal:  J Immunother Cancer       Date:  2019-05-06       Impact factor: 13.751

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.